Breakthrough in Blood: Cécile Denis and INSERM Team Develop Nanobody Therapy for Type 1 VWD
Cécile Denis, director of research at INSERM, shared a post on LinkedIn:
”The result of an almost 10-year journey: a bispecific nanobody bridging von Willebrand factor to albumin in order to prolong the half-life of VWF and increasing its plasma levels. A potential treatment for patients with decreased VWF levels (Type 1 VWD).
We should not forget that Von Willebrand disease remains largely underestimated and therefore untreated, especially in type 1 patients.
Thank you Ivan Peyron, Caterina Casari, Geneviève McCluskey, Stéphanie Roullet, Vincent Licari, Emilie BOCQUET, Claire Auditeau, Melanie Daniel, sophie susen, Olivier Christophe, Peter Lenting, HITh lab Inserm, INSERM, ANR Agence nationale de la recherche.”
Read the full study here.
Title: A bispecific nanobody for the treatment of von Willebrand disease type 1
Authors: Ivan Peyron, Caterina Casari, Genevieve McCluskey, Stéphanie Roullet, Vincent N Licari, Emilie Bocquet, Claire Auditeau, Melanie Y Daniel, Sophie Susen, Olivier D. Christophe, Peter J Lenting, Cécile V. Denis
Stay updated with Hemostasis Today.
-
Jul 27, 2026, 15:40Afila Thasnim: Blood Crossmatching Challenges and Safe Transfusion Decisions
-
Jul 27, 2026, 14:30William McKeown Elected Vice-President of the EHC
-
Jul 27, 2026, 13:54Nahid A. Qushmaq: Advancing Anticoagulation Through Factor XI/XIa Inhibition
-
Jul 27, 2026, 13:45The Essentials of FFP Dosing and Monitoring – ICHCC
-
Jul 27, 2026, 13:27Antonio Lauletta: Distinguishing Sporadic and ICI-Related MG-Myositis Overlap
-
Jul 27, 2026, 13:15Satyam Arora: Welcoming the New ISBT Board and Looking Ahead
-
Jul 27, 2026, 13:03Jeff Parke: Why We Are Losing Viable Kidneys in Transit
-
Jul 27, 2026, 12:58George Hajishengallis: A New Era in Periodontal Disease Treatment
-
Jul 27, 2026, 12:54Elena Masselli: Can Statins Enhance Peginterferon Therapy in MPNs?